Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy
BackgroundImmune checkpoint inhibitors (ICIs) improve survival in advanced cancers but are associated with immune-related adverse events (irAEs), whose prognostic impact remains debated. The role of systemic inflammatory biomarkers is also not fully de…